載入中
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
一般交易時段
US$1.585
−US$0.055 · -3.35%
盤中時間採用ET。市場資料可能有所延遲。
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
日內區間
目前US$1.585
52週區間
目前US$1.585
盤中時間採用ET。市場資料可能有所延遲。
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
日內區間
目前US$1.585
52週區間
目前US$1.585
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | 5.52萬 USD | 14.01萬 USD | 16.5萬 USD |
| 毛利 | — | — | 5.52萬 USD | 14.01萬 USD | 16.5萬 USD |
| 研究與開發 | 1021.28萬 USD | 1079.11萬 USD | 1152.06萬 USD | 837.73萬 USD | 716.42萬 USD |
| 銷售、一般及管理費用 | 849.79萬 USD | 955.95萬 USD | 1078.77萬 USD | 953.99萬 USD | 682.69萬 USD |
| 營業費用 | 1871.07萬 USD | 2035.06萬 USD | 2230.83萬 USD | 1791.72萬 USD | 1399.12萬 USD |
| 利息收入 | 24.44萬 USD | 35.71萬 USD | 49.42萬 USD | 37.54萬 USD | 1.25萬 USD |
| 折舊和攤銷 | 9.4萬 USD | 8.41萬 USD | 8.36萬 USD | 6.42萬 USD | 1.55萬 USD |
| 營業利益 | −1871.07萬 USD | −2035.06萬 USD | −2225.31萬 USD | −1777.7萬 USD | −1382.62萬 USD |
| 淨利 | −2016.11萬 USD | −2041.12萬 USD | −2226.75萬 USD | −1759.07萬 USD | −1389.06萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$5.00
上漲空間 215.46%報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
